Search results for: 'double dect bu'

In H1 2023, the APAC network firewall market saw a comparatively slower YoY growth of 8.2% as compared to H1 2022 that registered an estimated YoY growth of 14.0%. The market witnessed a slow growth following the difficult macroeconomic situation that engulfed many countries in APAC, leading to a more reserved approach when it comes to cybersecurit...

Compelling benefits, such as flexible capacity adjustments, rapid access to innovative features and capabilities, CAPEX avoidance, and ability to outsource routine solution management to an expert third party, will drive a steady shift to cloud communications services over the forecast period. Communications upgrades are increasingly a key part of ...

05 May 2017  |  Africa  |  Market Research

African Commercial Vehicles Market, Forecast to 2025

Despite Slowdown, the Market is Expected to Grow at a Robust CAGR of 6.1% until 2025, Driven by Increasing Infrastructure Developments

Infographics

×

The African commercial vehicles (CV) market, despite the slowdown due to low oil and commodity prices, is expected to grow at a compound annual growth rate (CAGR) of 6.1%, largely driven by increasing infrastructural developments and rising urbanisation. South Africa is the largest contributor to the CV market in Africa, with 53% share. However, un...

A total of 20.81 billion ride sharing services were offered in China in 2017. The overall ride sharing member size in China has achieved 207.4 million in 2017. The percent share breaks down as follows: commuting ride sharing 45.6%, dynamic ride sharing 32.3%, and fixed long distance ride sharing services 22.1%. Ride sharing services in China are o...

25 Nov 2020  |  North America  |  Market Research

Affected by the Steep Decline in Oil Prices due to the COVID-19 Pandemic, the Global Fluid Power Equipment Market is Gradually Recovering

Bleak Investment Activity and the Global Economic Shrinkage will Lead to a Short-term Market Contraction

Infographics

×

Key Issues Addressed

Owing to the US-China trade war and the global economic slowdown caused by the COVID-19 pandemic, the global fluid power equipment market is projected to face a sharp revenue contraction in 2020. Key end users, including oil and gas, aerospace and defense, and construction, are experiencing unprecedented declines due to the pandemic. The imposition...

Pharmaceutical drug discovery and development suffers from declining success rates with new molecules, and the rate of return has shrunk from 16% in 2011 to almost 11% in 2018. Frost & Sullivan finds that traditional solutions focused primarily on data from limited sources and rule-based computational techniques used to address the understanding of...

29 Jul 2021  |  Latin America  |  Market Research

Growth Opportunities in the Global Professional Headset Market, Forecast to 2027

An Indispensable Tool for Remote Workers During the Pandemic, Professional Headsets will be a Key Enabler of the Hybrid-work Future

Infographics

×

The global professional headset market earned revenues of $1.98 billion in 2020, a record growth of 42.3 percent when compared to 2019. In 2020, the coronavirus disease 2019 (COVID-19) pandemic and associated work from home (WFH) realities triggered unprecedented demand for cloud software communications and collaboration services and professional ...

The electrophysiology (EP) service line has grown leaps and bounds in the past decade, driven by factors including advancement in interventional imaging, improvement in catheters for effective ablation therapy, and the introduction of robotic navigation systems for supporting safe and efficient procedures. The demand for minimally invasive EP proce...

25 Apr 2022  |  North America  |  Frost Radar

Frost Radar™: Artificial Intelligence-enabled Drug Discovery, 2022

A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines

Infographics

×

Pharmaceutical drug discovery and development has been suffering from declining success rates with new molecules primarily because of poor external validity of preclinical models and lack of efficacy of the molecule in terms of the intended disease indication. Drug success rates continue to be in the range of only 1 in 10 that enters clinical phase...